Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
ConditionPTSD
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age19-70
SponsorWhite River Junction Veterans Affairs Medical Center
About this trial
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Eligibility criteria
Qualifiers
Age 19-70 years
Weight ≥ 45 kg
Diagnosed with PTSD as determined by the CAPS-5 within seven days of enrollment
Eligible for Veterans Affairs healthcare
Disqualifiers
None
Trial design
Treatments tested in this trial
- Glecaprevir/pibrentasvir
- Placebo
Treatment groups
92 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov